[1]
|
Wang H,Naghavi M,Allen C,et al. Global,regional,and national life expectancy,all-cause mortality,and cause-specific mortality for 249 causes of death,1980-2015:A systematic analysis for the global burden of disease study 2015[J]. Lancet,2016,388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1
|
[2]
|
Sung H,Ferlay J,Siegel R,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal For Clinicians,2021,70(4):1-41.
|
[3]
|
Ke H,Liang J,Zhang Y,et al. Conformational transition of fructose-1,6-bisphosphatase:Structure comparison between the AMP complex (T form) and the fructose 6-phosphate complex (R form)[J]. Biochemistry,1991,30(18):4412-4420. doi: 10.1021/bi00232a007
|
[4]
|
Moon S,Kim J,Han J,et al. Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis[J]. Metablism,2011,60(1):107-113. doi: 10.1016/j.metabol.2009.12.021
|
[5]
|
Gonzales P,Pisitkun T,Hoffert J,et al. Large-scale proteomics and phosphoproteomics of urinary exosomes[J]. J Am Soc Nephrol,2009,20(2):363-379. doi: 10.1681/ASN.2008040406
|
[6]
|
Consortium T U. UniProt:A worldwide hub of protein knowledge[J]. Nucleic Acids Research,2019,47(1):D506-D515. doi: 10.1093/nar/gky1049
|
[7]
|
Yánez A,Nualart F,Droppelmann C,et al. Broad expression of fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase provide evidence for gluconeogenesis in human tissues other than liver and kidney[J]. Journal of Cellular Physiology,2003,197(2):189-197. doi: 10.1002/jcp.10337
|
[8]
|
X L,X W,J Z,et al. Warburg effect revisited:An epigenetic link between glycolysis and gastric carcinogenesis[J]. Oncogene,2010,29(3):442-450. doi: 10.1038/onc.2009.332
|
[9]
|
Li J,Wang Y,Li Q G,et al. Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition[J]. PLoS One,2016,11(12):1-15.
|
[10]
|
Yu J,Li J,Chen Y,et al. Snail Enhances glycolysis in the epithelial-mesenchymal transition process by targeting FBP1 in gastric cancer[J]. Cell Physiol Biochem,2017,43(1):31-38. doi: 10.1159/000480314
|
[11]
|
Li B,Qiu B,Lee D S,et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression[J]. Nature,2014,513(7517):251-255. doi: 10.1038/nature13557
|
[12]
|
洪正东,朱安义,王艳华,等. FBP1在肾透明细胞癌组织中的表达变化及意义[J]. 重庆医学,2018,47(14):44-47.
|
[13]
|
R C, X Z, G H, et al. Fructose 1, 6-bisphosphatase 1 expression reduces 18F-FDG uptake in clear cell renal cell carcinoma[J]. Contrast Media & Molecular Imaging, 2019, 2019(期?): 1-6.R C,X Z,G H,et al. Fructose 1,6-bisphosphatase 1 expression reduces 18F-FDG uptake in clear cell renal cell carcinoma[J]. Contrast Media & Molecular Imaging,2019,2019:1-6.
|
[14]
|
Zhu Y,Shi M,Chen H,et al. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells[J]. Oncotarget,2015,6(25):21443-21451. doi: 10.18632/oncotarget.4167
|
[15]
|
Chen L Y,Cheng C S,Qu C,et al. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer[J]. Biochem Biophys Res Commun,2018,500(3):691-697. doi: 10.1016/j.bbrc.2018.04.137
|
[16]
|
Wang B,Fan P,Zhao J,et al. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res,2018,37(1):224-235. doi: 10.1186/s13046-018-0888-y
|
[17]
|
Jin X,Pan Y,Wang L,et al. Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction[J]. Cancer Research,2017,77(16):4328-4341. doi: 10.1158/0008-5472.CAN-16-3143
|
[18]
|
C Y,S Z,H Y,et al. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1[J]. American Journal of Cancer Research,2019,9(8):1722-1733.
|
[19]
|
Chen M,Zhang J,Li N,et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer[J]. PLoS One,2011,6(10):1-8.
|
[20]
|
J Y,C W,F Z,et al. Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect[J]. Carcinogenesis,2017,38(2):134-143.
|
[21]
|
Jin X,Pan Y,Wang L,et al. MAGE-TRIM28 complex promotes the warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation[J]. Oncogenesis,2017,6(4):1-12.
|
[22]
|
Ln Y,Zy N,L W,et al. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma[J]. American Journal of Cancer Research,2019,9(8):1607-1621.
|
[23]
|
Liu G M,Li Q,Zhang P F,et al. Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma[J]. Cell Death Dis,2018,9(11):1132-1141. doi: 10.1038/s41419-018-1165-x
|
[24]
|
Zhang D,Li Z,Li T,et al. miR-517a promotes Warburg effect in HCC by directly targeting FBP1[J]. Onco Targets Ther,2018,2018(11):8025-8032.
|
[25]
|
Li Q,Wei P,Wu J,et al. The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect[J]. Oncogene,2019,38(4):483-496. doi: 10.1038/s41388-018-0469-8
|
[26]
|
Iwatsuki M,Mimori K,Yokobori T,et al. Epithelial-mesenchymal transition in cancer development and its clinical significance[J]. Cancer Science,2010,101(2):293-299. doi: 10.1111/j.1349-7006.2009.01419.x
|
[27]
|
Dong C,Yuan T,Wu Y,et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer[J]. Cancer Cell,2013,23(3):316-331. doi: 10.1016/j.ccr.2013.01.022
|
[28]
|
Li K, Ying M, Feng D, et al. Fructose-1, 6-bisphosphatase is a novel regulator of Wnt/beta-Catenin pathway in breast cancer[J]. Biomed Pharmacother, 2016, 84(期?): 1144-1149.Li K,Ying M,Feng D,et al. Fructose-1,6-bisphosphatase is a novel regulator of Wnt/beta-Catenin pathway in breast cancer[J]. Biomed Pharmacother,2016,84:1144-1149.
|
[29]
|
Shi L,He C,Li Z,et al. FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1alpha[J]. Neoplasma,2017,64(4):535-542. doi: 10.4149/neo_2017_407
|
[30]
|
Fu D,Li J,Wei J,et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer[J]. Cell Commun Signal,2018,16(1):8-17. doi: 10.1186/s12964-018-0219-0
|
[31]
|
Shi L,Zhao C,Pu H,et al. FBP1 expression is associated with basal-like breast carcinoma[J]. Oncol Lett,2017,13(5):3046-3056. doi: 10.3892/ol.2017.5860
|
[32]
|
Chen J,Lee H-J,Wu X,et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain[J]. Cancer Research,2015,75(3):554-565. doi: 10.1158/0008-5472.CAN-14-2268
|
[33]
|
Sheng H,Ying L,Zheng L,et al. Down expression of FBP1 is a negative prognostic factor for non-small-cell lung cancer[J]. Cancer Invest,2015,33(5):197-204. doi: 10.3109/07357907.2015.1020385
|
[34]
|
Zhang J,Wang J,Xing H,et al. Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells[J]. Mol Cell Biochem,2016,411(1):331-340.
|
[35]
|
Dong Y,Huaying S,Danying W,et al. Significance of methylation of FBP1 gene in non-small cell lung cancer[J]. Biomed Res Int,2018,2018(9):1-9.
|
[36]
|
Dai Q,Li N,Zhou X. Increased miR-21a provides metabolic advantages through suppression of FBP1 expression in non-small cell lung cancer cells[J]. Am J Cancer Res,2017,7(11):2121-2130.
|